The NK1 receptor antagonist N-acetyl-l-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model

Parkinsonism and Related Disorders

Volumn 20, Issue 5, 2014, Pages 508-513

  Thornton, Emma ^a   Hassall, Mark Macquarie ^a   Corrigan, Frances ^a   Vink, Robert ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Dyskinesia; FosB; L DOPA; Motor function; Substance P; Tachykinin NK1 receptor

Indexed keywords

BENSERAZIDE; LEVODOPA; N ACETYLTRYPTOPHAN; OXIDOPAMINE; SUBSTANCE P; TRANSCRIPTION FACTOR FOSB; 3,5-BIS(TRIFLUOROMETHYL)BENZYL N-ACETYLTRYPTOPHAN; ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIPARKINSON AGENT; FOSB PROTEIN, RAT; N-ACETYLTRYPTOPHAN; PROTEIN C FOS; TRYPTOPHAN; TYROSINE 3 MONOOXYGENASE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DRUG ACTIVITY; DYSKINESIA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MONOTHERAPY; MOTOR PERFORMANCE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; ROTAROD TEST; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; ANIMAL; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; DYSKINESIA, DRUG-INDUCED; HEMISPHERIC DOMINANCE; MEDIAL FOREBRAIN BUNDLE; METABOLISM; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME; TOXICITY;

ADRENERGIC AGENTS; ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; FUNCTIONAL LATERALITY; LEVODOPA; MALE; MEDIAL FOREBRAIN BUNDLE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSONIAN DISORDERS; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TRYPTOPHAN; TYROSINE 3-MONOOXYGENASE;

EID: 84900017474     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2014.02.008     Document Type: Article

References (33)

1. Colosimo C., Merello M., Hughes A.J., Sieradzan K., Lees A.J. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. JNeurol Neurosurg Psychiatry 1996 Jun, 60(6):634-637.
2. Cenci M.A., Lindgren H.S. Advances in understanding L-DOPA-induced dyskinesia. Curr Opin Neurobiol 2007 Dec, 17(6):665-671.
3. Obeso J.A., Rodriguez-Oroz M., Marin C., Alonso F., Zamarbide I., Lanciego J.L., et al. The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 2004 Jan 13, 62(1 Suppl.1):S17-S30.
4. Rahman S., Griffin H.J., Quinn N.P., Jahanshahi M. Quality of life in Parkinson's disease: the relative importance of the symptoms. Mov Disord 2008 Jul 30, 23(10):1428-1434.
5. Jenner P. Preventing and controlling dyskinesia in Parkinson's disease - a view of current knowledge and future opportunities. Mov Disord 2008, 23(Suppl.3):S585-S598.
6. Lebel M., Chagniel L., Bureau G., Cyr M. Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat. Neurobiol Dis 2010 Apr, 38(1):59-67.
7. Westin J.E., Andersson M., Lundblad M., Cenci M.A. Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease. Eur J Neurosci 2001 Oct, 14(7):1171-1176.
8. Andersson M., Hilbertson A., Cenci M.A. Striatal FosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 1999 Dec, 6(6):461-474.
9. Cenci M.A., Lee C.S., Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998 Aug, 10(8):2694-2706.
10. Winkler C., Kirik D., Bjorklund A., Cenci M.A. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 2002 Jul, 10(2):165-186.
11. Cao X., Yasuda T., Uthayathas S., Watts R.L., Mouradian M.M., Mochizuki H., et al. Striatal overexpression of deltaFosB reproduces chronic levodopa-induced involuntary movements. JNeurosci 2010 May 26, 30(21):7335-7343.
12. Sutoo D., Yabe K., Akiyama K. Quantitative imaging of substance P in the human brain using a brain mapping analyzer. Neurosci Res 1999 Dec 30, 35(4):339-346.
13. Thornton E., Tran T.T., Vink R. Asubstance P mediated pathway contributes to 6-hydroxydopamine induced cell death. Neurosci Lett 2010 Aug 30, 481(1):64-67.
14. Engber T.M., Susel Z., Kuo S., Gerfen C.R., Chase T.N. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 1991 Jun 21, 552(1):113-118.
15. Mauborgne A., Javoy-Agid F., Legrand J.C., Agid Y., Cesselin F. Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains. Brain Res 1983 May 23, 268(1):167-170.
16. Paxinos G., Watson C. The rat brain stereotaxic coordinates 1998, Academis Press, San Diego. 4th ed.
17. Dekundy A., Lundblad M., Danysz W., Cenci M.A. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 2007 Apr 16, 179(1):76-89.
18. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 2002 Jan, 15(1):120-132.
19. Hamm R.J., Pike B.R., O'Dell D.M., Lyeth B.G., Jenkins L.W. The rotarod test: an evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. JNeurotrauma 1994 Apr, 11(2):187-196.
20. Rozas G., Guerra M.J., Labandeira-Garcia J.L. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res Brain Res Protoc 1997 Dec 1, 2(1):75-84.
21. Olsson M., Nikkhah G., Bentlage C., Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. JNeurosci 1995 May, 15(5 Pt 2):3863-3875.
22. Helps S.C., Thornton E., Kleinig T.J., Manavis J., Vink R. Automatic nonsubjective estimation of antigen content visualized by immunohistochemistry using color deconvolution. Appl Immunohistochem Mol Morphol 2012 Jan, 20(1):82-90.
23. Hanrieder J., Ljungdahl A., Falth M., Mammo S.E., Bergquist J., Andersson M. L-DOPA-induced dyskinesia is associated with regional increase of striatal dynorphin peptides as elucidated by imaging mass spectrometry. Mol Cell Proteomics 2011 Oct, 10(10). M111 009308.
24. Carta M., Lindgren H.S., Lundblad M., Stancampiano R., Fadda F., Cenci M.A. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. JNeurochem 2006 Mar, 96(6):1718-1727.
25. Eskow K.L., Dupre K.B., Barnum C.J., Dickinson S.O., Park J.Y., Bishop C. The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse 2009 Jul, 63(7):610-620. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
26. Lacoste B., Riad M., Descarries L. Immunocytochemical evidence for the existence of substance P receptor (NK1) in serotonin neurons of rat and mouse dorsal raphe nucleus. Eur J Neurosci 2006 Jun, 23(11):2947-2958. [Comparative Study Research Support, Non-U.S. Gov't].
27. Doucet J.P., Nakabeppu Y., Bedard P.J., Hope B.T., Nestler E.J., Jasmin B.J., et al. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. Eur J Neurosci 1996 Feb, 8(2):365-381.
28. Bishop C., Walker P.D. Intranigral antagonism of neurokinin 1 and 3 receptors reduces intrastriatal dopamine D1 receptor-stimulated locomotion in the rat. Brain Res 2004 Oct 8, 1023(1):126-133.
29. Chauhan V.S., Sterka D.G., Gray D.L., Bost K.L., Marriott I. Neurogenic exacerbation of microglial and astrocyte responses to Neisseria meningitidis and Borrelia burgdorferi. JImmunol 2008 Jun 15, 180(12):8241-8249.
30. Barnum C.J., Eskow K.L., Dupre K., Blandino P., Deak T., Bishop C. Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta. Neuroscience 2008 Sep 22, 156(1):30-41. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.].
31. Thornton E., Vink R. Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease. PLoS One 2012, 7(4):e34138. [Research Support, Non-U.S. Gov't].
32. Thornton E., Ziebell J.M., Leonard A.V., Vink R. Kinin receptor antagonists as potential neuroprotective agents in central nervous system injury. Molecules 2010 Sep, 15(9):6598-6618.
33. Westin J.E., Lindgren H.S., Gardi J., Nyengaard J.R., Brundin P., Mohapel P., et al. Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. JNeurosci 2006 Sep 13, 26(37):9448-9461.